Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease

IF 2 3区 医学 Q2 UROLOGY & NEPHROLOGY Advances in chronic kidney disease Pub Date : 2022-03-01 DOI:10.1053/j.ackd.2022.03.005
Arash Rashidi , Pranav S. Garimella , Abdullah Al-Asaad , Talar Kharadjian , Mariela Navarro Torres , Jyotsana Thakkar
{"title":"Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease","authors":"Arash Rashidi ,&nbsp;Pranav S. Garimella ,&nbsp;Abdullah Al-Asaad ,&nbsp;Talar Kharadjian ,&nbsp;Mariela Navarro Torres ,&nbsp;Jyotsana Thakkar","doi":"10.1053/j.ackd.2022.03.005","DOIUrl":null,"url":null,"abstract":"<div><p>Anemia is a common medical problem<span><span> among patients with cancer and chronic kidney disease (CKD). Although anemia </span>in patients<span> with CKD is often treated with iron and erythropoietin-stimulating agents, there are controversies with regard to the use of erythropoietin-stimulating agents in cancer patients. In this article, we review the treatment of anemia in patients with cancer and CKD, in addition to summarizing the current guidelines in treatment of anemia in these patients.</span></span></p></div>","PeriodicalId":7221,"journal":{"name":"Advances in chronic kidney disease","volume":"29 2","pages":"Pages 180-187.e1"},"PeriodicalIF":2.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in chronic kidney disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1548559522000556","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Anemia is a common medical problem among patients with cancer and chronic kidney disease (CKD). Although anemia in patients with CKD is often treated with iron and erythropoietin-stimulating agents, there are controversies with regard to the use of erythropoietin-stimulating agents in cancer patients. In this article, we review the treatment of anemia in patients with cancer and CKD, in addition to summarizing the current guidelines in treatment of anemia in these patients.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CKD合并终末期肾病的癌症患者的贫血管理
贫血是癌症和慢性肾脏疾病(CKD)患者常见的医学问题。虽然CKD患者的贫血通常用铁和促红细胞生成素治疗,但在癌症患者中使用促红细胞生成素仍存在争议。在这篇文章中,我们回顾了癌症和CKD患者贫血的治疗,并总结了目前治疗这些患者贫血的指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Advances in chronic kidney disease
Advances in chronic kidney disease 医学-泌尿学与肾脏学
自引率
3.40%
发文量
69
审稿时长
11.1 weeks
期刊介绍: The purpose of Advances Chronic Kidney Disease is to provide in-depth, scholarly review articles about the care and management of persons with early kidney disease and kidney failure, as well as those at risk for kidney disease. Emphasis is on articles related to the early identification of kidney disease; prevention or delay in progression of kidney disease
期刊最新文献
Masthead Editorial Board Table of Contents Current Trends and Challenges in Nephrology Fellowship Training: Expansion of Education in Home Dialysis, Palliative Care, and Point-of-Care Ultrasound Nephrology Education: Time for a Change
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1